Biogen Pharmachem Industries Board Approves 1:6 Bonus Share Issue and Capital Increase

Biogen Pharmachem Industries Limited's board of directors convened on March 23, 2026, to approve several major corporate actions that will significantly impact the company's capital structure. The meeting, held at the company's registered office from 07:00 PM to 07:30 PM, resulted in key decisions requiring shareholder approval through postal ballot.

Bonus Share Issuance Details

The board has recommended issuing fully paid-up bonus shares in a 1:6 ratio, providing shareholders with 1 new equity share for every 6 existing shares held. The bonus issue will create approximately 15,04,33,833 new equity shares of Rs. 1 each, funded through the company's securities premium account.

Parameter: Details Bonus Ratio: 1:6 (1 share for every 6 held) New Shares: 15,04,33,833 equity shares Face Value: Rs. 1 per share Funding Source: Securities Premium Account Amount Required: Rs. 15,04,33,833

Capital Structure Changes

The board approved increasing the company's authorized share capital substantially to accommodate future growth and the bonus issue.

Capital Structure: Pre-Bonus Post-Bonus Authorized Capital: Rs. 91,00,00,000 Rs. 1,08,00,00,000 Paid-up Capital: Rs. 90,26,03,000 Rs. 1,05,30,36,833 Number of Shares: 90,26,03,000 1,05,30,36,833

Financial Provisions and Timeline

The company maintains adequate reserves to support the bonus issue, with securities premium available as on March 31, 2025, totaling Rs. 17,00,00,000. This provides sufficient coverage for the required Rs. 15,04,33,833 for the bonus implementation. The new shares are expected to be credited within two months from the board approval date.

Additional Corporate Actions

The board addressed several other important matters during the meeting:

Statutory Auditor Appointment: Approved M/s. Goenka Mehta & Associates Chartered Accountants, Rajkot, as new statutory auditors to fill the casual vacancy caused by the resignation of M/s. Rishi Sekhri & Associates due to medical conditions

Memorandum Alteration: Recommended changes to the Capital Clause (Clause V) in the company's Memorandum of Association

Postal Ballot Process: Approved the draft notice for postal ballot and appointed M/s Daxa Negi & Associates as scrutinizer for the voting process

Shareholder Rights and Next Steps

The bonus shares, once allotted, will rank pari-passu with existing equity shares and carry identical rights. Shareholders will be entitled to participate in dividends and other corporate actions declared after the new shares are allotted. All proposed actions require shareholder approval through postal ballot, with the record date to be announced in due course.

The company has submitted the meeting outcomes to BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring compliance with regulatory requirements.

Biogen Pharmachem Industries Limited has formally notified the stock exchange about an upcoming board meeting to consider the declaration of bonus shares. The meeting represents a significant corporate development that could benefit existing shareholders through additional equity allocation.

Board Meeting Details

The company has scheduled the board meeting with specific parameters and regulatory compliance requirements:

Parameter: Details Meeting Date: March 23, 2026 Meeting Venue: Registered office of the company Primary Agenda: Declaration of bonus share issuance Regulatory Framework: SEBI (LODR) Regulations, 2015 Notification Date: February 24, 2026

Regulatory Compliance and Approval Process

The bonus share declaration falls under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has emphasized that the proposed bonus share issuance will be implemented in accordance with applicable provisions and remains subject to shareholder approval.

The formal intimation was communicated to BSE Limited, where the company trades under scrip code 531752. Wholetime Director Kelash Bunkar signed the official notification, ensuring proper corporate governance protocols are followed.

Company Information

Biogen Pharmachem Industries Limited operates with CIN number L51100GJ1995PLC026702, indicating its incorporation in Gujarat in 1995. The company maintains its registered office at Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001.

The bonus share consideration represents a potential value addition for existing shareholders, as such declarations typically indicate the company's confidence in its financial position and future prospects. However, the final decision will depend on board deliberations and subsequent shareholder approval through the prescribed corporate governance process.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.